Phase 3 Pipeline
10 programs
+1 program YoY
Added one small molecule, one ADC, and one oligonucleotide program; two moved to commercial.
COHANCELIFESCIENCES
Healthcare
15 May 2026
Cohance Lifesciences Ltd — Q4 FY26
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%).
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%). The CDMO segment was hit by destocking of two large commercial molecules (~₹260Cr impact) and delayed reloads, while API Plus declined 8% due to shipment delays and Nacharam site disruption. Specialty Chemicals fell 2.1% on program phasing. Management guided Q1 FY27 as the low point, with recovery from H2 driven by order conversion, new commercial launches (two molecules already commercialized, two more expected), and a strengthened phase 3 pipeline of 10 programs. Key risks include Middle East logistics cost inflation (100-150bps gross margin impact in Q1), delayed recovery of destocked molecules, and execution at NJ Bio (breakeven >2 years away). New CEO Omar Gora is focused on strategic blueprint, operational rigor, and deepening customer relationships.
Key Numbers
Active CDMO Projects
140+
flat YoY
Includes development and commercial programs across small molecules, ADCs, and oligonucleotides.
API Top 15 Leadership Products
~50% of API revenue
stable YoY
Eight of top 10 molecules hold leadership positions; portfolio remains differentiated.
R&D Spend as % of Revenue
16.2%
flat YoY
Continued investment in ADC and oligonucleotide capabilities.
Management Guidance
Q1 FY27 to be low point for revenue and EBITDA
Revenue and EBITDA in Q1 FY27 expected to be weak due to revenue schedules skewed to H2, logistics cost inflation, and higher operating costs.
Management guidance revenueGrowth to return from H2 FY27
Recovery expected in second half of FY27, driven by order conversion, reloads, and improving utilization across the platform.
Management guidance growthCapex of ~₹3B in FY27
Capital expenditure focused on ADC and oligonucleotide manufacturing infrastructure and quality systems.
Management guidance capexGross margin impact of 100-150 bps in Q1 FY27 from Middle East logistics
Escalation in logistics and input costs due to Middle East geopolitical situation will impact gross margins, mainly in API Plus business.
Management guidance marginsKey Risks
Delayed recovery of destocked molecules
Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.
high · analyst_questionMiddle East logistics cost inflation
Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.
medium · management_commentaryNJ Bio profitability timeline extended
NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.
medium · management_commentaryCustomer concentration in CDMO
Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk.
high · data_observationNotable Quotes
My immediate priority over the next few months will be to spend time with our teams, customers and sites. By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation.
We believe the business is moving towards a bottoming out phase with quarter 1 FY27 to be the low point.
The challenges during FY26 were concentrated around a limited set of products and customer specific situations rather than reflecting any structural weakness in the portfolio.
Frequently Asked Questions
What was Cohance Lifesciences's revenue in Q4 FY26?
Cohance Lifesciences reported revenue of ₹619 Cr in Q4 FY26, representing a -13% change compared to the same quarter last year.
What guidance did Cohance Lifesciences management give for FY27?
Q1 FY27 to be low point for revenue and EBITDA: Revenue and EBITDA in Q1 FY27 expected to be weak due to revenue schedules skewed to H2, logistics cost inflation, and higher operating costs. Growth to return from H2 FY27: Recovery expected in second half of FY27, driven by order conversion, reloads, and improving utilization across the platform. Capex of ~₹3B in FY27: Capital expenditure focused on ADC and oligonucleotide manufacturing infrastructure and quality systems. Gross margin impact of 100-150 bps in Q1 FY27 from Middle East logistics: Escalation in logistics and input costs due to Middle East geopolitical situation will impact gross margins, mainly in API Plus business.
What are the key risks for Cohance Lifesciences in FY27?
Key risks include Delayed recovery of destocked molecules — Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.; Middle East logistics cost inflation — Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.; NJ Bio profitability timeline extended — NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.; Customer concentration in CDMO — Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk..
Did Cohance Lifesciences meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Cohance Lifesciences Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.